{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,6,3]],"date-time":"2026-06-03T16:00:18Z","timestamp":1780502418923,"version":"3.54.1"},"reference-count":27,"publisher":"Springer Science and Business Media LLC","content-domain":{"domain":[],"crossmark-restriction":false},"short-container-title":[],"published-print":{"date-parts":[[2026,6,3]]},"DOI":"10.7759\/cureus.110182","type":"journal-article","created":{"date-parts":[[2026,6,3]],"date-time":"2026-06-03T15:00:02Z","timestamp":1780498802000},"source":"Crossref","is-referenced-by-count":0,"title":["Efficacy and Safety of Bruton Tyrosine Kinase Inhibitors in Waldenstr\u00f6m Macroglobulinemia: A Single-Center Retrospective Analysis"],"prefix":"10.7759","author":[{"given":"Mitali","family":"Singh","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Dibakar","family":"Podder","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Arjin P","family":"Jacoby","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Saswata","family":"Saha","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Soumyadip","family":"Chatterji","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Shouriyo","family":"Ghosh","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Debranjani","family":"Chattopadhyay","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Jeevan","family":"Kumar","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Arijit","family":"Nag","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Rizwan","family":"Javed","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Asish","family":"Rath","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Subhosmito","family":"Chakraborty","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Rakesh","family":"Demde","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Pralay","family":"Ghosh","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Mayur","family":"Parihar","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Lateef","family":"Zameer","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Gaurav","family":"Goel","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Sanjay","family":"Bhattacharya","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Pampi","family":"Majumder","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Mammen","family":"Chandy","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Reena","family":"Nair","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"297","reference":[{"key":"ref1","doi-asserted-by":"publisher","DOI":"10.1053\/sonc.2003.50082","article-title":"Clinicopathological definition of Waldenstrom's macroglobulinemia: consensus panel recommendations from the Second International Workshop on Waldenstrom's Macroglobulinemia","volume":"30","author":"Owen RG","year":"2003","unstructured":"Owen RG, Treon SP, Al-Katib A, et al.. Clinicopathological definition of Waldenstrom's macroglobulinemia: consensus panel recommendations from the Second International Workshop on Waldenstrom's Macroglobulinemia. Semin Oncol. 2003, 30:110-5. 10.1053\/sonc.2003.50082","journal-title":"Semin Oncol"},{"key":"ref2","doi-asserted-by":"publisher","DOI":"10.1111\/j.0954-6820.1944.tb03955.x","article-title":"Incipient myelomatosis or \u00abessential\u00ab hyperglobulinemia with fibrinogenopenia \u2014 a new syndrome?","volume":"117","author":"Waldenstr\u00f6m J","year":"1944","unstructured":"Waldenstr\u00f6m J. Incipient myelomatosis or \u00abessential\u00ab hyperglobulinemia with fibrinogenopenia \u2014 a new syndrome?. Acta Med Scand. 1944, 117:216-47. 10.1111\/j.0954-6820.1944.tb03955.x","journal-title":"Acta Med Scand"},{"key":"ref3","doi-asserted-by":"publisher","DOI":"10.1002\/ajh.27666","article-title":"Waldenstr\u00f6m macroglobulinemia: 2025 update on diagnosis, risk stratification, and management","volume":"100","author":"Gertz MA","year":"2025","unstructured":"Gertz MA. Waldenstr\u00f6m macroglobulinemia: 2025 update on diagnosis, risk stratification, and management. Am J Hematol. 2025, 100:1061-73. 10.1002\/ajh.27666","journal-title":"Am J Hematol"},{"key":"ref4","doi-asserted-by":"publisher","DOI":"10.1056\/NEJMoa1200710","article-title":"MYD88 L265P somatic mutation in Waldenstr\u00f6m's macroglobulinemia","volume":"367","author":"Treon SP","year":"2012","unstructured":"Treon SP, Xu L, Yang G, et al.. MYD88 L265P somatic mutation in Waldenstr\u00f6m's macroglobulinemia. N Engl J Med. 2012, 367:826-33. 10.1056\/NEJMoa1200710","journal-title":"N Engl J Med"},{"key":"ref5","doi-asserted-by":"publisher","DOI":"10.1182\/blood-2013-09-525808","article-title":"The genomic landscape of Waldenstrom macroglobulinemia is characterized by highly recurring MYD88 and WHIM-like CXCR4 mutations, and small somatic deletions associated with B-cell lymphomagenesis","volume":"123","author":"Hunter ZR","year":"2014","unstructured":"Hunter ZR, Xu L, Yang G, et al.. The genomic landscape of Waldenstrom macroglobulinemia is characterized by highly recurring MYD88 and WHIM-like CXCR4 mutations, and small somatic deletions associated with B-cell lymphomagenesis. Blood. 2014, 123:1637-46. 10.1182\/blood-2013-09-525808","journal-title":"Blood"},{"key":"ref6","doi-asserted-by":"publisher","DOI":"10.1200\/JCO.2018.78.6426","article-title":"Ibrutinib monotherapy in symptomatic, treatment-na\u00efve patients with Waldenstr\u00f6m macroglobulinemia","volume":"36","author":"Treon SP","year":"2018","unstructured":"Treon SP, Gustine J, Meid K, et al.. Ibrutinib monotherapy in symptomatic, treatment-na\u00efve patients with Waldenstr\u00f6m macroglobulinemia. J Clin Oncol. 2018, 36:2755-61. 10.1200\/JCO.2018.78.6426","journal-title":"J Clin Oncol"},{"key":"ref7","doi-asserted-by":"publisher","DOI":"10.3324\/haematol.2023.284588","article-title":"Rituximab plus cyclophosphamide and dexamethasone versus bortezomib plus cyclophosphamide and dexamethasone in newly diagnosed symptomatic Waldenstr\u00f6m macroglobulinemia: a randomized controlled trial","volume":"109","author":"Xiong W","year":"2024","unstructured":"Xiong W, Lyu R, Yu Y, et al.. Rituximab plus cyclophosphamide and dexamethasone versus bortezomib plus cyclophosphamide and dexamethasone in newly diagnosed symptomatic Waldenstr\u00f6m macroglobulinemia: a randomized controlled trial. Haematologica. 2024, 109:1614-8. 10.3324\/haematol.2023.284588","journal-title":"Haematologica"},{"key":"ref8","doi-asserted-by":"publisher","DOI":"10.1007\/s00277-022-05019-y","article-title":"Bortezomib-based chemotherapy for patients with Waldenstr\u00f6m macroglobulinemia: a single-center experience","volume":"102","author":"Liu Z","year":"2023","unstructured":"Liu Z, Jiang S, Gu J, Liu H, Song G, Cao X. Bortezomib-based chemotherapy for patients with Waldenstr\u00f6m macroglobulinemia: a single-center experience. Ann Hematol. 2023, 102:167-74. 10.1007\/s00277-022-05019-y","journal-title":"Ann Hematol"},{"key":"ref9","doi-asserted-by":"publisher","DOI":"10.1080\/10428194.2018.1508668","article-title":"Carfilzomib-based combination regimens are highly effective frontline therapies for multiple myeloma and Waldenstr\u00f6m's macroglobulinemia","volume":"60","author":"Chaudhry M","year":"2019","unstructured":"Chaudhry M, Steiner R, Claussen C, et al.. Carfilzomib-based combination regimens are highly effective frontline therapies for multiple myeloma and Waldenstr\u00f6m's macroglobulinemia. Leuk Lymphoma. 2019, 60:964-70. 10.1080\/10428194.2018.1508668","journal-title":"Leuk Lymphoma"},{"key":"ref10","doi-asserted-by":"publisher","DOI":"10.1056\/NEJMoa1501548","article-title":"Ibrutinib in previously treated Waldenstr\u00f6m's macroglobulinemia","volume":"372","author":"Treon SP","year":"2015","unstructured":"Treon SP, Tripsas CK, Meid K, et al.. Ibrutinib in previously treated Waldenstr\u00f6m's macroglobulinemia. N Engl J Med. 2015, 372:1430-40. 10.1056\/NEJMoa1501548","journal-title":"N Engl J Med"},{"key":"ref11","doi-asserted-by":"publisher","DOI":"10.1200\/JCO.22.02830","article-title":"Zanubrutinib versus ibrutinib in symptomatic Waldenstr\u00f6m macroglobulinemia: final analysis from the randomized phase III ASPEN study","volume":"41","author":"Dimopoulos MA","year":"2023","unstructured":"Dimopoulos MA, Opat S, D'Sa S, et al.. Zanubrutinib versus ibrutinib in symptomatic Waldenstr\u00f6m macroglobulinemia: final analysis from the randomized phase III ASPEN study. J Clin Oncol. 2023, 41:5099-106. 10.1200\/JCO.22.02830","journal-title":"J Clin Oncol"},{"key":"ref12","doi-asserted-by":"publisher","DOI":"10.1016\/S2352-3026(19)30210-8","article-title":"Acalabrutinib monotherapy in patients with Waldenstr\u00f6m macroglobulinemia: a single-arm, multicentre, phase 2 study","volume":"7","author":"Owen RG","year":"2020","unstructured":"Owen RG, McCarthy H, Rule S, et al.. Acalabrutinib monotherapy in patients with Waldenstr\u00f6m macroglobulinemia: a single-arm, multicentre, phase 2 study. Lancet Haematol. 2020, 7:e112-21. 10.1016\/S2352-3026(19)30210-8","journal-title":"Lancet Haematol"},{"key":"ref13","doi-asserted-by":"publisher","DOI":"10.1016\/S0140-6736(21)00224-5","article-title":"Pirtobrutinib in relapsed or refractory B-cell malignancies (BRUIN): a phase 1\/2 study","volume":"397","author":"Mato AR","year":"2021","unstructured":"Mato AR, Shah NN, Jurczak W, et al.. Pirtobrutinib in relapsed or refractory B-cell malignancies (BRUIN): a phase 1\/2 study. Lancet. 2021, 397:892-901. 10.1016\/S0140-6736(21)00224-5","journal-title":"Lancet"},{"key":"ref14","doi-asserted-by":"publisher","DOI":"10.1002\/ajh.26788","article-title":"Bruton tyrosine kinase inhibitors in the management of Waldenstr\u00f6m macroglobulinemia","volume":"98","author":"Castillo JJ","year":"2023","unstructured":"Castillo JJ, Buske C, Trotman J, Sarosiek S, Treon SP. Bruton tyrosine kinase inhibitors in the management of Waldenstr\u00f6m macroglobulinemia. Am J Hematol. 2023, 98:338-47. 10.1002\/ajh.26788","journal-title":"Am J Hematol"},{"key":"ref15","doi-asserted-by":"publisher","DOI":"10.1111\/bjh.12102","article-title":"Response assessment in Waldenstr\u00f6m macroglobulinaemia: update from the VIth International Workshop","volume":"160","author":"Owen RG","year":"2013","unstructured":"Owen RG, Kyle RA, Stone MJ, et al.. Response assessment in Waldenstr\u00f6m macroglobulinaemia: update from the VIth International Workshop. Br J Haematol. 2013, 160:171-6. 10.1111\/bjh.12102","journal-title":"Br J Haematol"},{"key":"ref16","doi-asserted-by":"publisher","DOI":"10.1001\/jama.2013.281053","article-title":"World Medical Association Declaration of Helsinki: ethical principles for medical research involving human subjects","volume":"310","year":"2013","unstructured":"World Medical Association Declaration of Helsinki. ethical principles for medical research involving human subjects. JAMA. 2013, 310:2191-4. 10.1001\/jama.2013.281053","journal-title":"JAMA"},{"key":"ref17","doi-asserted-by":"publisher","DOI":"10.1200\/JCO.20.00555","article-title":"Long-term follow-up of ibrutinib monotherapy in symptomatic, previously treated patients with Waldenstr\u00f6m macroglobulinemia","volume":"39","author":"Treon SP","year":"2021","unstructured":"Treon SP, Meid K, Gustine J, et al.. Long-term follow-up of ibrutinib monotherapy in symptomatic, previously treated patients with Waldenstr\u00f6m macroglobulinemia. J Clin Oncol. 2021, 39:565-75. 10.1200\/JCO.20.00555","journal-title":"J Clin Oncol"},{"key":"ref18","doi-asserted-by":"publisher","DOI":"10.1159\/000542936","article-title":"\"Real-life\" data of zanubrutinib in patients with Waldenstr\u00f6m macroglobulinemia: a multicenter retrospective study","volume":"148","author":"Itchaki G","year":"2025","unstructured":"Itchaki G, Benjamini O, Levi M, et al.. \"Real-life\" data of zanubrutinib in patients with Waldenstr\u00f6m macroglobulinemia: a multicenter retrospective study. Acta Haematol. 2025, 148:462-7. 10.1159\/000542936","journal-title":"Acta Haematol"},{"key":"ref19","doi-asserted-by":"publisher","DOI":"10.1158\/1078-0432.CCR-21-1497","article-title":"Single-agent ibrutinib for rituximab-refractory Waldenstr\u00f6m macroglobulinemia: final analysis of the substudy of the phase III Innovate(TM) trial","volume":"27","author":"Trotman J","year":"2021","unstructured":"Trotman J, Buske C, Tedeschi A, et al.. Single-agent ibrutinib for rituximab-refractory Waldenstr\u00f6m macroglobulinemia: final analysis of the substudy of the phase III Innovate(TM) trial. Clin Cancer Res. 2021, 27:5793-800. 10.1158\/1078-0432.CCR-21-1497","journal-title":"Clin Cancer Res"},{"key":"ref20","doi-asserted-by":"publisher","DOI":"10.1097\/01.HS9.0000847388.33116.c7","article-title":"P1130: acalabrutinib in treatment-naive or relapsed\/refractory Waldenstr\u00f6m macroglobulinemia: 5-year follow-up of a phase 2, single-arm study","volume":"6","author":"Owen R","year":"2022","unstructured":"Owen R, McCarthy H, Rule S, et al.. P1130: acalabrutinib in treatment-naive or relapsed\/refractory Waldenstr\u00f6m macroglobulinemia: 5-year follow-up of a phase 2, single-arm study. Hemasphere. 2022, 6:1020-1. 10.1097\/01.HS9.0000847388.33116.c7","journal-title":"Hemasphere"},{"key":"ref21","doi-asserted-by":"publisher","DOI":"10.1093\/cid\/ciy175","article-title":"Serious infections in patients receiving ibrutinib for treatment of lymphoid cancer","volume":"67","author":"Varughese T","year":"2018","unstructured":"Varughese T, Taur Y, Cohen N, Palomba ML, Seo SK, Hohl TM, Redelman-Sidi G. Serious infections in patients receiving ibrutinib for treatment of lymphoid cancer. Clin Infect Dis. 2018, 67:687-92. 10.1093\/cid\/ciy175","journal-title":"Clin Infect Dis"},{"key":"ref22","doi-asserted-by":"publisher","DOI":"10.1182\/blood.2022018818","article-title":"Detailed safety profile of acalabrutinib vs ibrutinib in previously treated chronic lymphocytic leukemia in the ELEVATE-RR trial","volume":"142","author":"Seymour JF","year":"2023","unstructured":"Seymour JF, Byrd JC, Ghia P, et al.. Detailed safety profile of acalabrutinib vs ibrutinib in previously treated chronic lymphocytic leukemia in the ELEVATE-RR trial. Blood. 2023, 142:687-99. 10.1182\/blood.2022018818","journal-title":"Blood"},{"key":"ref23","doi-asserted-by":"publisher","DOI":"10.64898\/2026.04.10.26350611","article-title":"Clinico-pathologic characteristics, patterns of treatment and outcome of newly diagnosed Waldenstr\u00f6ms Macroglobulinemia- a single center real world retrospective analysis","author":"Gupta V","year":"2026","unstructured":"Gupta V, Podder D, Saha S, et al.. Clinico-pathologic characteristics, patterns of treatment and outcome of newly diagnosed Waldenstr\u00f6ms Macroglobulinemia- a single center real world retrospective analysis. medRxiv. 2026, 10.64898\/2026.04.10.26350611","journal-title":"medRxiv"},{"key":"ref24","doi-asserted-by":"publisher","DOI":"10.1002\/ajh.26210","article-title":"Assessment of fixed-duration therapies for treatment-na\u00efve Waldenstr\u00f6m macroglobulinemia","volume":"96","author":"Abeykoon JP","year":"2021","unstructured":"Abeykoon JP, Zanwar S, Ansell SM, et al.. Assessment of fixed-duration therapies for treatment-na\u00efve Waldenstr\u00f6m macroglobulinemia. Am J Hematol. 2021, 96:945-53. 10.1002\/ajh.26210","journal-title":"Am J Hematol"},{"key":"ref25","doi-asserted-by":"publisher","DOI":"10.1111\/bjh.19409","article-title":"Long-term results of Waldenstr\u00f6m macroglobulinaemia treatment by bendamustine and rituximab: a study on behalf of the French Innovative Leukemia Organization (FILO)","volume":"204","author":"Laribi K","year":"2024","unstructured":"Laribi K, Poulain S, Willems L, et al.. Long-term results of Waldenstr\u00f6m macroglobulinaemia treatment by bendamustine and rituximab: a study on behalf of the French Innovative Leukemia Organization (FILO). Br J Haematol. 2024, 204:2233-6. 10.1111\/bjh.19409","journal-title":"Br J Haematol"},{"key":"ref26","doi-asserted-by":"publisher","DOI":"10.1016\/j.cmi.2024.12.032","article-title":"Fungal infection in patients treated with Bruton tyrosine kinase inhibitor-from epidemiology to clinical outcome: a systematic review","volume":"31","author":"Gibert C","year":"2025","unstructured":"Gibert C, Blaize M, Fekkar A. Fungal infection in patients treated with Bruton tyrosine kinase inhibitor-from epidemiology to clinical outcome: a systematic review. Clin Microbiol Infect. 2025, 31:731-9. 10.1016\/j.cmi.2024.12.032","journal-title":"Clin Microbiol Infect"},{"key":"ref27","doi-asserted-by":"publisher","DOI":"10.1186\/s13613-023-01219-5","article-title":"Severe infections requiring intensive care unit admission in patients receiving ibrutinib for hematological malignancies: a groupe de recherche respiratoire en r\u00e9animation onco-h\u00e9matologique (GRRR-OH) study","volume":"13","author":"Baucher L","year":"2023","unstructured":"Baucher L, Lemiale V, Joseph A, et al.. Severe infections requiring intensive care unit admission in patients receiving ibrutinib for hematological malignancies: a groupe de recherche respiratoire en r\u00e9animation onco-h\u00e9matologique (GRRR-OH) study. Ann Intensive Care. 2023, 13:123. 10.1186\/s13613-023-01219-5","journal-title":"Ann Intensive Care"}],"container-title":["Cureus"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/www.cureus.com\/articles\/499576-efficacy-and-safety-of-bruton-tyrosine-kinase-inhibitors-in-waldenstrm-macroglobulinemia-a-single-center-retrospective-analysis","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2026,6,3]],"date-time":"2026-06-03T15:00:03Z","timestamp":1780498803000},"score":1,"resource":{"primary":{"URL":"https:\/\/www.cureus.com\/articles\/499576-efficacy-and-safety-of-bruton-tyrosine-kinase-inhibitors-in-waldenstrm-macroglobulinemia-a-single-center-retrospective-analysis"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2026,6,3]]},"references-count":27,"URL":"https:\/\/doi.org\/10.7759\/cureus.110182","relation":{},"ISSN":["2168-8184"],"issn-type":[{"value":"2168-8184","type":"print"}],"subject":[],"published":{"date-parts":[[2026,6,3]]}}}